Literature DB >> 33863821

Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects.

Alexandra Gogola1, Davneet S Minhas1, Victor L Villemagne2, Ann D Cohen2, James M Mountz1, Tharick A Pascoal2, Charles M Laymon1,3, N Scott Mason1, Milos D Ikonomovic2,4, Chester A Mathis1, Beth E Snitz4, Oscar L Lopez4, William E Klunk2, Brian J Lopresti5.   

Abstract

Tau PET tracers exhibit varying levels of specific signal and distinct off-target binding patterns that are more diverse than amyloid PET tracers. This study compared 2 frequently used tau PET tracers, 18F-flortaucipir and 18F-MK-6240, in the same subjects.
Methods: 18F-flortaucipir and 18F-MK-6240 scans were collected within 2 mo in 15 elderly subjects varying in clinical diagnosis and cognition. FreeSurfer, version 5.3, was applied to 3-T MR images to segment Braak pathologic regions (I-VI) for PET analyses. Off-target binding was assessed in the choroid plexus, meninges, and striatum. SUV ratio (SUVR) outcomes were determined over 80-100 min (18F-flortaucipir) or 70-90 min (18F-MK-6240) normalized to cerebellar gray matter. Masked visual interpretation of images was performed by 5 raters for both the medial temporal lobe and the neocortex, and an overall (majority) rating was determined.
Results: Overall visual ratings showed complete concordance between radiotracers for both the medial temporal lobe and the neocortex. SUVR outcomes were highly correlated (r 2 > 0.92; P ≪ 0.001) for all Braak regions except Braak II. The dynamic range of SUVRs in target regions was approximately 2-fold higher for 18F-MK-6240 than for 18F-flortaucipir. Cerebellar SUVs were similar for 18F-MK-6240 and 18F-flortaucipir, suggesting that differences in SUVRs are driven by specific signals. Apparent off-target binding was observed often in the striatum and choroid plexus with 18F-flortaucipir and most often in the meninges with 18F-MK-6240.
Conclusion: Both 18F-MK-6240 and 18F-flortaucipir are capable of quantifying signal in a common set of brain regions that develop tau pathology in Alzheimer disease; these tracers perform equally well in visual interpretations. Each also shows distinct patterns of apparent off-target binding. 18F-MK-6240 showed a greater dynamic range in SUVR estimates, which may be an advantage in detecting early tau pathology or in performing longitudinal studies to detect small interval changes.
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  18F-MK-6240; 18F-flortaucipir; Alzheimer disease; PET; tau

Mesh:

Substances:

Year:  2021        PMID: 33863821      PMCID: PMC8717175          DOI: 10.2967/jnumed.120.254961

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   11.082


  53 in total

1.  Amyloid PET Imaging: Standardization and Integration with Other Alzheimer's Disease Biomarkers.

Authors:  Silvia Morbelli; Matteo Bauckneht
Journal:  Methods Mol Biol       Date:  2018

2.  Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs).

Authors:  Abbas M Walji; Eric D Hostetler; Harold Selnick; Zhizhen Zeng; Patricia Miller; Idriss Bennacef; Cristian Salinas; Brett Connolly; Liza Gantert; Marie Holahan; Stacey O'Malley; Mona Purcell; Kerry Riffel; Jing Li; Jaume Balsells; Julie A OBrien; Stacey Melquist; Aileen Soriano; Xiaoping Zhang; Aimie Ogawa; Serena Xu; Elizabeth Joshi; Joseph Della Rocca; Fred J Hess; Joel Schachter; David Hesk; David Schenk; Arie Struyk; Kerim Babaoglu; Talakad G Lohith; Yaode Wang; Kun Yang; Jianmin Fu; Jeffrey L Evelhoch; Paul J Coleman
Journal:  J Med Chem       Date:  2016-05-05       Impact factor: 7.446

3.  Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease.

Authors:  Sergey Shcherbinin; Adam J Schwarz; Abhinay Joshi; Michael Navitsky; Matthew Flitter; William R Shankle; Michael D Devous; Mark A Mintun
Journal:  J Nucl Med       Date:  2016-05-05       Impact factor: 10.057

4.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.

Authors:  Rik Ossenkoppele; Daniel R Schonhaut; Michael Schöll; Samuel N Lockhart; Nagehan Ayakta; Suzanne L Baker; James P O'Neil; Mustafa Janabi; Andreas Lazaris; Averill Cantwell; Jacob Vogel; Miguel Santos; Zachary A Miller; Brianne M Bettcher; Keith A Vossel; Joel H Kramer; Maria L Gorno-Tempini; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  Brain       Date:  2016-03-08       Impact factor: 13.501

5.  The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

Authors:  William E Klunk; Robert A Koeppe; Julie C Price; Tammie L Benzinger; Michael D Devous; William J Jagust; Keith A Johnson; Chester A Mathis; Davneet Minhas; Michael J Pontecorvo; Christopher C Rowe; Daniel M Skovronsky; Mark A Mintun
Journal:  Alzheimers Dement       Date:  2014-10-28       Impact factor: 21.566

6.  Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies.

Authors:  Marta Marquié; Marc D Normandin; Avery C Meltzer; Michael Siao Tick Chong; Nicolas V Andrea; Alejandro Antón-Fernández; William E Klunk; Chester A Mathis; Milos D Ikonomovic; Manik Debnath; Elizabeth A Bien; Charles R Vanderburg; Isabel Costantino; Sara Makaretz; Sarah L DeVos; Derek H Oakley; Stephen N Gomperts; John H Growdon; Kimiko Domoto-Reilly; Diane Lucente; Bradford C Dickerson; Matthew P Frosch; Bradley T Hyman; Keith A Johnson; Teresa Gómez-Isla
Journal:  Ann Neurol       Date:  2017-01       Impact factor: 10.422

7.  Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects.

Authors:  Nicolas J Guehl; Dustin W Wooten; Daniel L Yokell; Sung-Hyun Moon; Maeva Dhaynaut; Samantha Katz; Kirsten A Moody; Codi Gharagouzloo; Aurélie Kas; Keith A Johnson; Georges El Fakhri; Marc D Normandin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-22       Impact factor: 9.236

8.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

9.  18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.

Authors:  Luca Passamonti; Patricia Vázquez Rodríguez; Young T Hong; Kieren S J Allinson; David Williamson; Robin J Borchert; Saber Sami; Thomas E Cope; W Richard Bevan-Jones; P Simon Jones; Robert Arnold; Ajenthan Surendranathan; Elijah Mak; Li Su; Tim D Fryer; Franklin I Aigbirhio; John T O'Brien; James B Rowe
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

10.  In vivo quantification of neurofibrillary tangles with [18F]MK-6240.

Authors:  Tharick A Pascoal; Monica Shin; Min Su Kang; Mira Chamoun; Daniel Chartrand; Sulantha Mathotaarachchi; Idriss Bennacef; Joseph Therriault; Kok Pin Ng; Robert Hopewell; Reda Bouhachi; Hung-Hsin Hsiao; Andrea L Benedet; Jean-Paul Soucy; Gassan Massarweh; Serge Gauthier; Pedro Rosa-Neto
Journal:  Alzheimers Res Ther       Date:  2018-07-31       Impact factor: 6.982

View more
  8 in total

1.  Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern.

Authors:  Greet Vanderlinden; Jenny Ceccarini; Thomas Vande Casteele; Laura Michiels; Robin Lemmens; Eric Triau; Kim Serdons; Jos Tournoy; Michel Koole; Mathieu Vandenbulcke; Koen Van Laere
Journal:  Mol Psychiatry       Date:  2022-07-06       Impact factor: 15.992

2.  Impact of meningeal uptake and partial volume correction techniques on [18F]MK-6240 binding in aMCI patients and healthy controls.

Authors:  Nathalie Mertens; Laura Michiels; Greet Vanderlinden; Mathieu Vandenbulcke; Robin Lemmens; Koen Van Laere; Michel Koole
Journal:  J Cereb Blood Flow Metab       Date:  2022-01-21       Impact factor: 6.960

3.  Mesial temporal tau in amyloid-β-negative cognitively normal older persons.

Authors:  Natasha Krishnadas; Vincent Doré; Colin Groot; Fiona Lamb; Pierrick Bourgeat; Samantha C Burnham; Kun Huang; Anita M Y Goh; Colin L Masters; Victor L Villemagne; Christopher C Rowe
Journal:  Alzheimers Res Ther       Date:  2022-04-08       Impact factor: 8.823

Review 4.  Tauopathies: new perspectives and challenges.

Authors:  Yi Zhang; Kai-Min Wu; Liu Yang; Qiang Dong; Jin-Tai Yu
Journal:  Mol Neurodegener       Date:  2022-04-07       Impact factor: 14.195

Review 5.  Imaging Clinical Subtypes and Associated Brain Networks in Alzheimer's Disease.

Authors:  Karl Herholz
Journal:  Brain Sci       Date:  2022-01-23

6.  Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation.

Authors:  Justin P Wright; Jason R Goodman; Yin-Guo Lin; Brian P Lieberman; Jennifer Clemens; Luis F Gomez; Qianwa Liang; Adam T Hoye; Michael J Pontecorvo; Kelly A Conway
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-21       Impact factor: 10.057

7.  Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease.

Authors:  Natasha Krishnadas; Kun Huang; Stephanie A Schultz; Vincent Doré; Pierrick Bourgeat; Anita M Y Goh; Fiona Lamb; Svetlana Bozinovski; Samantha C Burnham; Joanne S Robertson; Simon M Laws; Paul Maruff; Colin L Masters; Victor L Villemagne; Christopher C Rowe
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

Review 8.  Imaging pathological tau in atypical parkinsonisms: A review.

Authors:  Anastassia M Mena; Antonio P Strafella
Journal:  Clin Park Relat Disord       Date:  2022-07-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.